Samuel Starke,Keziah Thomas,Supriya Jasuja,Ronald Lubelchek
In a U.S. health department TB program serving primarily non-U.S.-born clients, 78% of those evaluated for latent TB infection initiated TB preventive therapy, with 71% completing treatment. Completion was lower among newly arrived migrants. A novel one-month isoniazid-rifapentine regimen (1HP) was well tolerated, with similar completion rates to conventional regimens.
{"title":"Short-Course Tuberculosis Preventive Therapy in a High Migration Setting: Early Experience With 1HP in Cook County, Illinois.","authors":"Samuel Starke,Keziah Thomas,Supriya Jasuja,Ronald Lubelchek","doi":"10.1093/cid/ciaf723","DOIUrl":"https://doi.org/10.1093/cid/ciaf723","url":null,"abstract":"In a U.S. health department TB program serving primarily non-U.S.-born clients, 78% of those evaluated for latent TB infection initiated TB preventive therapy, with 71% completing treatment. Completion was lower among newly arrived migrants. A novel one-month isoniazid-rifapentine regimen (1HP) was well tolerated, with similar completion rates to conventional regimens.","PeriodicalId":10463,"journal":{"name":"Clinical Infectious Diseases","volume":"36 1","pages":""},"PeriodicalIF":11.8,"publicationDate":"2026-01-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146005022","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Chin Fen Neoh,Sharon C-A Chen,Arthur J Morris,Christopher H Heath,Shu Jin Tan,Rebekah Lane,Shio Yen Tio,Sze Yen Tay,Matthew B Roberts,Karina Kennedy,Sebastiaan J van Hal,Hugh C Murray,Robert Pickles,Natasha Marcella Vaselli,Abby Douglas,Karen Urbancic,Mahesh Menon,Adam Stewart,Julia C Howard,Caitlin Keighley,Spiros Miyakis,Rohan Beresford,Louise Cooley,Marjoree Sehu,Catriona L Halliday,Sarah Kidd,David C M Kong,Tim Spelman,Leon J Worth,Monica A Slavin,
BACKGROUNDUnderstanding the epidemiology of invasive non-Aspergillus mold infections is essential to inform effective therapy. Robust regional studies remain scarce. This study aimed to determine the epidemiology and infection characteristics of non-Aspergillus mold infections in Australasia.METHODSA 21-center, retrospective study of proven/probable non-Aspergillus mold infections from 2016 to 2023 was conducted in Australia and New Zealand. Data collected included demographic, clinical, microbiological, treatment and outcome information until 180 days of follow-up.RESULTSOf 421 cases, 346 (82.2%) were proven infections and 315 (74.8%) were localized. Lung (n=150/421, 35.6%) was the most common site of infection. Twenty cases (4.8%) were due to >1 non-Aspergillus mold pathogen, resulting in 443 isolates altogether. Dematiaceous molds, inclusive of Lomentospora prolificans (n=96, 21.7%), Scedosporium spp. (n=87, 19.6%) and other dematiaceous molds of various genera (n=48, 10.8%), were the most common (n=231, 52.1%), followed by Mucorales (n=141, 31.8%). Common underlying conditions were hematological malignancy (n=146/421, 34.7%) and diabetes mellitus (n=122/421, 29.0%) while 68 cases (16.2%) had no comorbidities. Lymphopenia was present in 46.6% (n=196/421). One-third (n=138/421, 32.8%) received antifungal prophylaxis 30 days before non-Aspergillus mold diagnosis and L. prolificans was the most common cause of breakthrough infections (p<0.001). All-cause 90-day mortality was 31.4% (n=132/421), with higher mortality observed in L. prolificans (n=51/89, 57.3%) and Mucorales (n=56/129, 43.4%) infections.CONCLUSIONSL. prolificans, Scedosporium spp. and Mucorales are the most frequent non-Aspergillus mold pathogens in Australasia, with other emerging species and mixed infections encountered. Mortality from L. prolificans and Mucorales infections remains high.
{"title":"Current Epidemiology and Infection Characteristics of Non-Aspergillus Mold Infections: A Multicenter Study in Australia and New Zealand.","authors":"Chin Fen Neoh,Sharon C-A Chen,Arthur J Morris,Christopher H Heath,Shu Jin Tan,Rebekah Lane,Shio Yen Tio,Sze Yen Tay,Matthew B Roberts,Karina Kennedy,Sebastiaan J van Hal,Hugh C Murray,Robert Pickles,Natasha Marcella Vaselli,Abby Douglas,Karen Urbancic,Mahesh Menon,Adam Stewart,Julia C Howard,Caitlin Keighley,Spiros Miyakis,Rohan Beresford,Louise Cooley,Marjoree Sehu,Catriona L Halliday,Sarah Kidd,David C M Kong,Tim Spelman,Leon J Worth,Monica A Slavin, ","doi":"10.1093/cid/ciag029","DOIUrl":"https://doi.org/10.1093/cid/ciag029","url":null,"abstract":"BACKGROUNDUnderstanding the epidemiology of invasive non-Aspergillus mold infections is essential to inform effective therapy. Robust regional studies remain scarce. This study aimed to determine the epidemiology and infection characteristics of non-Aspergillus mold infections in Australasia.METHODSA 21-center, retrospective study of proven/probable non-Aspergillus mold infections from 2016 to 2023 was conducted in Australia and New Zealand. Data collected included demographic, clinical, microbiological, treatment and outcome information until 180 days of follow-up.RESULTSOf 421 cases, 346 (82.2%) were proven infections and 315 (74.8%) were localized. Lung (n=150/421, 35.6%) was the most common site of infection. Twenty cases (4.8%) were due to >1 non-Aspergillus mold pathogen, resulting in 443 isolates altogether. Dematiaceous molds, inclusive of Lomentospora prolificans (n=96, 21.7%), Scedosporium spp. (n=87, 19.6%) and other dematiaceous molds of various genera (n=48, 10.8%), were the most common (n=231, 52.1%), followed by Mucorales (n=141, 31.8%). Common underlying conditions were hematological malignancy (n=146/421, 34.7%) and diabetes mellitus (n=122/421, 29.0%) while 68 cases (16.2%) had no comorbidities. Lymphopenia was present in 46.6% (n=196/421). One-third (n=138/421, 32.8%) received antifungal prophylaxis 30 days before non-Aspergillus mold diagnosis and L. prolificans was the most common cause of breakthrough infections (p<0.001). All-cause 90-day mortality was 31.4% (n=132/421), with higher mortality observed in L. prolificans (n=51/89, 57.3%) and Mucorales (n=56/129, 43.4%) infections.CONCLUSIONSL. prolificans, Scedosporium spp. and Mucorales are the most frequent non-Aspergillus mold pathogens in Australasia, with other emerging species and mixed infections encountered. Mortality from L. prolificans and Mucorales infections remains high.","PeriodicalId":10463,"journal":{"name":"Clinical Infectious Diseases","volume":"36 1","pages":""},"PeriodicalIF":11.8,"publicationDate":"2026-01-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146005023","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"The clinical thermometer as the first home test for infectious disease.","authors":"Michele Augusto Riva","doi":"10.1093/cid/ciag030","DOIUrl":"https://doi.org/10.1093/cid/ciag030","url":null,"abstract":"","PeriodicalId":10463,"journal":{"name":"Clinical Infectious Diseases","volume":"41 1","pages":""},"PeriodicalIF":11.8,"publicationDate":"2026-01-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146005026","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Emily A Rosen,Elizabeth M Krantz,Allison Thibodeau,Keara Kennedy,Leah H Yoke,Frank Tverdek,Zahra Kassamali Escobar,Jason P Cooper,Masumi Ueda Oshima,Paul Hendrie,Marco Mielcarek,Catherine Liu
BACKGROUNDThe optimal frequency of repeat blood cultures in persistent febrile neutropenia (FN) remains unknown. This study aims to identify opportunities for blood culture diagnostic stewardship in persistent FN.METHODSThis is a retrospective cohort study of patients with hematology/oncology diagnoses and an FN episode >3 days. Generalized estimating equation logistic regression models were used to evaluate risk factors for new bloodstream infection (BSI) after FN day 3.RESULTSAmong 620 patients, median FN duration was 5 days and median blood culture bottles collected per patient was 12. On FN day 1, 25% of patients had a positive blood culture; on FN days 2-9, <5% of patients per day had a new organism isolated. Among 31 new organisms isolated after FN day 3, 8 (26%) were contaminants. Of 503 patients with ≥1 blood culture collected after FN day 3, 19 (4%) had a new BSI after FN day 3. FN onset in the peri-hematopoietic cell transplant (HCT) period (day -7 to +30) was associated with lower odds of new BSI after FN day 3 (OR 0.18; 95%CI [0.04-0.71]; p=0.01).Thirty-six patients died within 30 days after FN day 3, including 4 with a new BSI after FN day 3; 1 death was attributable to BSI after FN day 3.CONCLUSIONSDetection of new BSI after FN day 3 was uncommon, demonstrating low diagnostic yield of repeat blood cultures after FN day 3. FN episodes in the peri-HCT period may be a potential focus for blood culture diagnostic stewardship initiatives.
{"title":"Diagnostic Yield of Repeat Blood Cultures and Risk Factors for Bloodstream Infection in Persistent Febrile Neutropenia.","authors":"Emily A Rosen,Elizabeth M Krantz,Allison Thibodeau,Keara Kennedy,Leah H Yoke,Frank Tverdek,Zahra Kassamali Escobar,Jason P Cooper,Masumi Ueda Oshima,Paul Hendrie,Marco Mielcarek,Catherine Liu","doi":"10.1093/cid/ciag014","DOIUrl":"https://doi.org/10.1093/cid/ciag014","url":null,"abstract":"BACKGROUNDThe optimal frequency of repeat blood cultures in persistent febrile neutropenia (FN) remains unknown. This study aims to identify opportunities for blood culture diagnostic stewardship in persistent FN.METHODSThis is a retrospective cohort study of patients with hematology/oncology diagnoses and an FN episode >3 days. Generalized estimating equation logistic regression models were used to evaluate risk factors for new bloodstream infection (BSI) after FN day 3.RESULTSAmong 620 patients, median FN duration was 5 days and median blood culture bottles collected per patient was 12. On FN day 1, 25% of patients had a positive blood culture; on FN days 2-9, <5% of patients per day had a new organism isolated. Among 31 new organisms isolated after FN day 3, 8 (26%) were contaminants. Of 503 patients with ≥1 blood culture collected after FN day 3, 19 (4%) had a new BSI after FN day 3. FN onset in the peri-hematopoietic cell transplant (HCT) period (day -7 to +30) was associated with lower odds of new BSI after FN day 3 (OR 0.18; 95%CI [0.04-0.71]; p=0.01).Thirty-six patients died within 30 days after FN day 3, including 4 with a new BSI after FN day 3; 1 death was attributable to BSI after FN day 3.CONCLUSIONSDetection of new BSI after FN day 3 was uncommon, demonstrating low diagnostic yield of repeat blood cultures after FN day 3. FN episodes in the peri-HCT period may be a potential focus for blood culture diagnostic stewardship initiatives.","PeriodicalId":10463,"journal":{"name":"Clinical Infectious Diseases","volume":"30 1","pages":""},"PeriodicalIF":11.8,"publicationDate":"2026-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146005031","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Subcutaneous antibiotic administration is increasingly recognized as a valuable alternative to intravenous therapy in selected clinical contexts. It is particularly advantageous for patients with poor venous access, frail or cachectic individuals, and in outpatient or palliative care settings, when oral options are not feasible. Subcutaneous delivery of antibiotics with predominantly time-dependent activity, particularly β-lactams (eg ceftriaxone, ertapenem) and glycopeptides (teicoplanin), allows attainment of therapeutic pharmacokinetic/pharmacodynamic (PK/PD) targets comparable to intravenous administration, while maintaining stable concentrations and reducing catheter-related complications. By contrast, PK/PD benefits are limited for agents with more concentration-dependent activity, such as aminoglycosides and fluoroquinolones due to reduced peak levels and local toxicity, whereas daptomycin shows favorable exposure and target attainment with acceptable tolerability. Available evidence suggests good tolerability, although regulatory frameworks remain limited. This multidisciplinary review, authored by infectious disease specialists, clinical pharmacologists, and nurses, summarizes current clinical experience, PK/PD data, and technical aspects of subcutaneous infusion.
{"title":"When and How to Use Subcutaneous Antibiotics.","authors":"Stefano Di Bella,Nicholas Geremia,Federico Pea,Markus Zeitlinger,Gianfranco Sanson,Jacopo Monticelli,Felix Bergmann,Christian Motet,Christophe Lambotte-Buffet,Verena Zerbato,Milo Gatti","doi":"10.1093/cid/ciaf691","DOIUrl":"https://doi.org/10.1093/cid/ciaf691","url":null,"abstract":"Subcutaneous antibiotic administration is increasingly recognized as a valuable alternative to intravenous therapy in selected clinical contexts. It is particularly advantageous for patients with poor venous access, frail or cachectic individuals, and in outpatient or palliative care settings, when oral options are not feasible. Subcutaneous delivery of antibiotics with predominantly time-dependent activity, particularly β-lactams (eg ceftriaxone, ertapenem) and glycopeptides (teicoplanin), allows attainment of therapeutic pharmacokinetic/pharmacodynamic (PK/PD) targets comparable to intravenous administration, while maintaining stable concentrations and reducing catheter-related complications. By contrast, PK/PD benefits are limited for agents with more concentration-dependent activity, such as aminoglycosides and fluoroquinolones due to reduced peak levels and local toxicity, whereas daptomycin shows favorable exposure and target attainment with acceptable tolerability. Available evidence suggests good tolerability, although regulatory frameworks remain limited. This multidisciplinary review, authored by infectious disease specialists, clinical pharmacologists, and nurses, summarizes current clinical experience, PK/PD data, and technical aspects of subcutaneous infusion.","PeriodicalId":10463,"journal":{"name":"Clinical Infectious Diseases","volume":"88 1","pages":""},"PeriodicalIF":11.8,"publicationDate":"2026-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146005242","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Michihiko Goto,Anindita Bandyopadhyay,Qianyi Shi,Yaohua Wang,Eli N Perencevich,David Hernandez,W Nick Street
BACKGROUNDConventional hospital antibiograms summarize aggregated resistance rates, limiting their utility for individualized antimicrobial selection. Existing statistical and machine learning models predict each phenotype separately, ignoring correlations among resistance profiles. We developed novel multi-task extreme gradient boosting (XGBoost) models utilizing structured data in electronic health records (EHRs) to predict resistance to eight antimicrobial classes simultaneously and evaluated their performance within the Veterans Health Administration (VHA).METHODSWe conducted a retrospective multicenter study of Escherichia coli and Klebsiella spp. isolates collected at 127 hospitals and >1,400 clinics from January 2017 to September 2024. Data from January 2017 to September 2023 were used for model development, while data from October 2023 to September 2024 were used for simulated prospective testing. Model performances were compared to hospital antibiograms and single-target XGBoost models.RESULTSThe training cohort included 536,252 E. coli and 246,898 Klebsiella spp. isolates; the test cohort included 75,138 and 38,015 isolates, respectively. On the test data, the multi-task model achieved overall areas under the receiver operating characteristic curve (AUROCs) of 0.779 (E. coli) and 0.810 (Klebsiella spp.), with good to excellent per-class performance (AUROCs range: 0.743-0.847). A multi-task approach improved calibration and decreased false negative rates for carbapenem resistance, while predicting individualized resistance probabilities for all target antimicrobials simultaneously ("personalized antibiograms").CONCLUSIONSA multi-task XGBoost framework can accurately predict individualized resistance profiles for common Gram-negative pathogens, outperforming conventional antibiograms and single-target models. Personalized antibiograms may enhance the selection of empiric therapy, including the detection of carbapenem resistance in low-endemicity settings.
{"title":"Personalized Antibiogram: A Novel Multi-Task Machine Learning Framework for Simultaneous Prediction of Antimicrobial Resistance Profile with Enhanced Detection of Carbapenem Resistance in Enterobacteriaceae.","authors":"Michihiko Goto,Anindita Bandyopadhyay,Qianyi Shi,Yaohua Wang,Eli N Perencevich,David Hernandez,W Nick Street","doi":"10.1093/cid/ciag027","DOIUrl":"https://doi.org/10.1093/cid/ciag027","url":null,"abstract":"BACKGROUNDConventional hospital antibiograms summarize aggregated resistance rates, limiting their utility for individualized antimicrobial selection. Existing statistical and machine learning models predict each phenotype separately, ignoring correlations among resistance profiles. We developed novel multi-task extreme gradient boosting (XGBoost) models utilizing structured data in electronic health records (EHRs) to predict resistance to eight antimicrobial classes simultaneously and evaluated their performance within the Veterans Health Administration (VHA).METHODSWe conducted a retrospective multicenter study of Escherichia coli and Klebsiella spp. isolates collected at 127 hospitals and >1,400 clinics from January 2017 to September 2024. Data from January 2017 to September 2023 were used for model development, while data from October 2023 to September 2024 were used for simulated prospective testing. Model performances were compared to hospital antibiograms and single-target XGBoost models.RESULTSThe training cohort included 536,252 E. coli and 246,898 Klebsiella spp. isolates; the test cohort included 75,138 and 38,015 isolates, respectively. On the test data, the multi-task model achieved overall areas under the receiver operating characteristic curve (AUROCs) of 0.779 (E. coli) and 0.810 (Klebsiella spp.), with good to excellent per-class performance (AUROCs range: 0.743-0.847). A multi-task approach improved calibration and decreased false negative rates for carbapenem resistance, while predicting individualized resistance probabilities for all target antimicrobials simultaneously (\"personalized antibiograms\").CONCLUSIONSA multi-task XGBoost framework can accurately predict individualized resistance profiles for common Gram-negative pathogens, outperforming conventional antibiograms and single-target models. Personalized antibiograms may enhance the selection of empiric therapy, including the detection of carbapenem resistance in low-endemicity settings.","PeriodicalId":10463,"journal":{"name":"Clinical Infectious Diseases","volume":"40 1","pages":""},"PeriodicalIF":11.8,"publicationDate":"2026-01-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145986280","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Vincent Lo Re, Jennifer C Price, Steven Schmitt, Norah Terrault, Debika Bhattacharya, Andrew Arohnson
{"title":"The Obstacle is the Way: Finding a Path to Hepatitis C Elimination.","authors":"Vincent Lo Re, Jennifer C Price, Steven Schmitt, Norah Terrault, Debika Bhattacharya, Andrew Arohnson","doi":"10.1093/cid/ciae231","DOIUrl":"10.1093/cid/ciae231","url":null,"abstract":"","PeriodicalId":10463,"journal":{"name":"Clinical Infectious Diseases","volume":" ","pages":"i47-i50"},"PeriodicalIF":7.3,"publicationDate":"2026-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140944130","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"American Thoracic Society/Centers for Disease Control and Prevention/European Respiratory Society/Infectious Diseases Society of America (ATS/CDC/ERS/IDSA) Updated Guideline on the Treatment of Tuberculosis.","authors":"Sonal S Munsiff","doi":"10.1093/cid/ciaf066","DOIUrl":"10.1093/cid/ciaf066","url":null,"abstract":"","PeriodicalId":10463,"journal":{"name":"Clinical Infectious Diseases","volume":" ","pages":"i46"},"PeriodicalIF":7.3,"publicationDate":"2026-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143413622","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Nandita Nadig, Adarsh Bhimraj, Kelly Cawcutt, Kathleen Chiotos, Amy L Dzierba, Arthur Y Kim, Greg S Martin, Jeffrey C Pearson, Amy Hirsch Shumaker, Lindsey R Baden, Roger Bedimo, Vincent Chi-Chung Cheng, Kara W Chew, Eric S Daar, David V Glidden, Erica J Hardy, Steven Johnson, Jonathan Z Li, Christine MacBrayne, Mari M Nakamura, Laura Riley, Robert W Shafer, Shmuel Shoham, Pablo Tebas, Phyllis C Tien, Jennifer Loveless, Yngve Falck-Ytter, Rebecca L Morgan, Rajesh T Gandhi
This article provides a focused update to the clinical practice guideline on the treatment and management of patients with coronavirus disease 2019 (COVID-19), developed by the Infectious Diseases Society of America. The guideline panel presents a recommendation on the use of infliximab in hospitalized adults with severe or critical COVID-19. The recommendation is based on evidence derived from a systematic literature review and adheres to a standardized methodology for rating the certainty of evidence and strength of recommendation according to the GRADE (Grading of Recommendations, Assessment, Development, and Evaluation) approach.
{"title":"2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Infliximab.","authors":"Nandita Nadig, Adarsh Bhimraj, Kelly Cawcutt, Kathleen Chiotos, Amy L Dzierba, Arthur Y Kim, Greg S Martin, Jeffrey C Pearson, Amy Hirsch Shumaker, Lindsey R Baden, Roger Bedimo, Vincent Chi-Chung Cheng, Kara W Chew, Eric S Daar, David V Glidden, Erica J Hardy, Steven Johnson, Jonathan Z Li, Christine MacBrayne, Mari M Nakamura, Laura Riley, Robert W Shafer, Shmuel Shoham, Pablo Tebas, Phyllis C Tien, Jennifer Loveless, Yngve Falck-Ytter, Rebecca L Morgan, Rajesh T Gandhi","doi":"10.1093/cid/ciaf355","DOIUrl":"10.1093/cid/ciaf355","url":null,"abstract":"<p><p>This article provides a focused update to the clinical practice guideline on the treatment and management of patients with coronavirus disease 2019 (COVID-19), developed by the Infectious Diseases Society of America. The guideline panel presents a recommendation on the use of infliximab in hospitalized adults with severe or critical COVID-19. The recommendation is based on evidence derived from a systematic literature review and adheres to a standardized methodology for rating the certainty of evidence and strength of recommendation according to the GRADE (Grading of Recommendations, Assessment, Development, and Evaluation) approach.</p>","PeriodicalId":10463,"journal":{"name":"Clinical Infectious Diseases","volume":" ","pages":"i22-i26"},"PeriodicalIF":7.3,"publicationDate":"2026-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12809853/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144882348","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：